| ALDEYRA THERAPEUT.DL-,001 |
| USA |
| Gesundheit |
| US01438T1060 / A111X8 |
| 137 (Frankfurt) / ALDX (NASDAQ) |
| FRA:137, ETR:137, 137:GR, NASDAQ:ALDX |
| - |
| https://www.aldeyra.com/ |
|
Aldeyra Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing therapies for immune-mediated and metabolic diseases. Its proprietary reactive aldehyde species (RASP) modulator platform underpins key product ..
>Volltext.. |
| 81.19 Mio. EUR |
| 34.75 Mio. EUR |
| - |
| -29.9 Mio. EUR |
| -28.9 Mio. EUR |
| -0.48 EUR |
| 13.26 Mio. EUR |
| 59.8 Mio. EUR |
| -28.47 Mio. EUR |
| 2.52 |
| - |
| 46.59% |
| - |
| - |
| - |
| - |
| ALDEYRA |
| 02.05.26 |
|
||||
|
||||
|
||||
|
||||
|